

BioPorto's gRAD platform validated for QIAGEN's ESEQuant lateral flow system

BioPorto Diagnostics and QIAGEN have successfully validated the use of BioPorto's gRAD lateral flow platform on QIAGEN's ESEQuant LR3 Lateral Flow System.

By combining gRAD with the ESEQuant LRS system, this platform, provides a powerful and versatile toolbox for rapid development of lateral flow-based assays. This toolbox is well suited in the constantly shifting lateral flow market space, where the demand for new applications in human diagnostics, veterinary diagnostics, food industry and environmental/agriculture testing is rapidly increasing.

Jan Kuhlmann Andersen, COO of BioPorto, commented: "With the gRAD platform BioPorto Diagnostics has the ability to offer assay developers across several industries contract development of their assay development. Through the combination of gRAD and the ESEQuant LRS system, BioPorto now has a complete assay development process in place to test across above mentioned business segments."

Read more about the gRAD lateral flow technology and the ESEQuant LR3 Lateral Flow technology.



www.bioporto.com/Products/Product-by-category/Lateral-flow.aspx



<http://www.lateralflowreader.com/new-powerful-option-esequant-lr3-grad/>

For further information, please contact:

Peter Mørch Eriksen, CEO

Gry Husby Larsen, General Counsel

Telephone +45 4529 0000, e-mail investor@bioporto.com